Tocqueville Asset Management L.P. Sells 87,500 Shares of Progyny, Inc. (NASDAQ:PGNY)

Tocqueville Asset Management L.P. trimmed its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 51.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,000 shares of the company’s stock after selling 87,500 shares during the period. Tocqueville Asset Management L.P.’s holdings in Progyny were worth $1,449,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares during the last quarter. Signaturefd LLC increased its holdings in Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after acquiring an additional 1,526 shares during the last quarter. KBC Group NV increased its holdings in Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares during the last quarter. Finally, Entropy Technologies LP increased its holdings in Progyny by 5.5% in the 4th quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock valued at $826,000 after acquiring an additional 2,499 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Canaccord Genuity Group lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Bank of America lifted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.82.

Progyny Trading Up 2.4 %

PGNY stock opened at $21.71 on Thursday. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $38.98. The company has a 50-day moving average price of $21.80 and a 200 day moving average price of $18.61. The stock has a market cap of $1.85 billion, a PE ratio of 37.43, a P/E/G ratio of 2.39 and a beta of 1.41.

Insider Buying and Selling

In other news, CEO Peter Anevski purchased 209,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman David J. Schlanger acquired 150,000 shares of the stock in a transaction on Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.